Tafinlar® (dabrafenib), Mekinist® (trametinib) – New indication
June 23, 2022 - Novartis announced the FDA approval of Tafinlar (dabrafenib) plus Mekinist (trametinib), for the treatment of adult and pediatric patients 6 years of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options.
Top